Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-center, Single-arm Phase IIa Study to Evaluate the Safety and Efficacy of Vebreltinib in Combination with Osimertinib in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer with EGFR 21 L858R Mutation

NCT06827145 is registered in ClinicalTrials.gov with National Cancer Center, China as lead sponsor.

NCT NCT06827145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06827145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-center, Single-arm Phase IIa Study to Evaluate the Safety and Efficacy of Vebreltinib in Combination with Osimertinib in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer with EGFR 21 L858R Mutation
Lead sponsor
National Cancer Center, China
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 14, 2024
Completion date
September 30, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung cancer